Herbal Life Limited reported strong Q2 2026 financial results, including a 5.8% year-over-year sales increase on a constant currency basis. The company highlighted strategic investments driving growth, with a focus on personalized nutrition innovations and expanding market reach. Adjusted EBITDA met guidance, signaling business resilience and execution progress.

Herbalife leverages technology, science, and human connection to lead in personalized nutrition, exemplified by Bionic Go and Protocol, integrating AI and biomarker insights for tailored health solutions.

Following significant updates based on distributor feedback, the company is focusing on smart device integrations, biomarker support, and a beta blood testing program. Additionally, Life IO, a healthy lifespan brand, is being introduced to cater to a growing market interested in long-term health and vitality. Products like Baseline, Helio, and Activate Energy are part of this expansion, aiming to simplify consumers' wellness routines and strengthen the company's position in the healthy lifespan market.

The dialogue emphasizes the pivotal role of distributors in translating AI-driven personalized nutrition insights into actionable outcomes, fostering customer engagement and motivation. It highlights global extravaganza events as platforms for distributor education and networking, strengthening the Herbalife brand. The Fuel like Ronaldo campaign exemplifies strategic marketing leveraging celebrity partnerships to expand brand reach. Personalized nutrition integration across products, technology, and a vast network is presented as a competitive advantage, underscoring the company's commitment to innovation and distributor success.

Herbalife's outgoing president, strategic, and financial officer will retire, succeeded by Scott Schaefer as CFO. Q2 net sales grew 5.8% year-over-year to $1.3 billion, with adjusted EBITDA at $167 million, reflecting strong performance despite FX headwinds. A pre-tax debt extinguishment loss impacted GAAP net loss, but adjusted net income was $53 million. Operating cash flow for H1 2026 was $147 million, up 57% YoY, showcasing robust cash generation.

Ed reported robust net sales growth, with worldwide volume increasing 5.8%, marking the fourth consecutive quarter of year-over-year growth. North America saw a return to slight growth, driven by higher pricing. Regional sales improved sequentially, despite challenges from country mix and FX. Pricing contributed a $37 million benefit, offsetting mix and currency headwinds.

Latin America achieved its fourth consecutive quarter of double-digit growth, with net sales up 17% and constant currency results up 8%. Asia Pacific also reported strong growth, with net sales increasing 15% and constant currency net sales up 23%, driven by volume growth and favorable pricing. Despite challenges in EMEA and China, the company projects modest growth for the third quarter and full year, with adjusted EBITDA guidance raised on a constant currency basis. Capital expenditures and SaaS implementation costs are also outlined, reflecting strategic financial planning.

Discusses Herbalife's strong free cash flow yield, debt reduction commitment, and CFO leadership transition for continued financial stability and growth.

The dialogue discusses strategies for enhancing distributor retention and productivity in the Asia Pacific and North America regions. In Asia Pacific, particularly India, growth is attributed to strong business models, customer support, and pricing adjustments. In North America, increased productivity among distributors, especially new entrants, is noted, with a significant rise in nutrition club productivity. The conversation also touches on upcoming product launches and their potential impact on reaching more sophisticated consumers.

The dialogue explains the reduction in CapEx range as a result of disciplined project review and ROI analysis, leading to underspending rather than deferring projects to the next year, emphasizing investment in value-adding initiatives over financial constraints.

The dialogue emphasizes the importance of prioritizing capital expenditures to add value through strategic project investments, not due to cash constraints. It highlights the growth in North America's market and the expansion of protein products, discussing how this trend benefits the company by increasing market share and consumer awareness, positioning it as a leader in health and wellbeing products.

The dialogue discusses the impact of inflation on input costs, particularly for proteins, packaging, and freight due to oil price hikes. Despite these pressures, the speaker indicates that the effects are manageable and anticipates cost recovery through standard pricing adjustments for the upcoming year.

The CFO reassures that current capital allocation priorities remain stable, emphasizing board-level decisions and no immediate changes expected despite new leadership. The focus is on maintaining investor clarity regarding financial strategies.

The acquisition of Thorn by P&G, a premium supplement company, is seen as validation of the strategy in the personalized nutrition market. The move is interpreted as a natural progression for the company, highlighting the direction towards targeting a broader audience. The acquisition, valued at $3.8 billion, reflects confidence in the $34 billion global personalized nutrition market and underscores the competitive environment within premium nutritional supplements.

The beta test of an at-home blood biomarker diagnostics system has been launched in North America, aiming to offer affordable and accessible personalized health insights. Initial reactions from distributors have been positive, focusing on the ease of use, from ordering to result integration into health protocols. With recent investments in the personalized nutrition market, including blood-based testing, this innovation marks a significant step in health diagnostics evolution. Upcoming expansions, including the launch of Thionic in Europe and North America, highlight the company's commitment to advancing personalized health solutions.

The speaker highlights Herbalife's 45-year proven business model, emphasizing its leadership in personalized nutrition through a vast network of distributors. The company is leveraging market opportunities to invest in growth, reduce debt, and create shareholder value, concluding with gratitude to employees, distributors, and shareholders.